{"nctId":"NCT01268891","briefTitle":"Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea","startDateStruct":{"date":"2011-01"},"conditions":["Parkinson's Disease"],"count":132,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Azilect®","type":"EXPERIMENTAL","interventionNames":["Drug: Azilect®"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Azilect®","otherNames":["Rasagiline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with idiopathic PD\n* Patients with motor fluctuations averaging at least 1 hour daily in the OFF state during the waking hours (not including morning akinesia)\n* Patients with a Modified Hoehn and Yahr stage \\<5 in the OFF state\n* Patients taking optimised levodopa/DOPA decarboxylase inhibitor (DDI) therapy for at least 14 days prior to baseline\n* Patients receiving at least 3 daily doses of levodopa, not including a bedtime dose, and not more than 8 daily doses of levodopa\n* Patient who have demonstrated the ability to keep accurate 24-hour diaries prior to randomisation\n\nExclusion Criteria:\n\n* Patients with a clinically significant or unstable medical or surgical condition that would preclude his/her safe and complete study participation\n* Patients taking any disallowed medication according to the Azilect® approved label\n* Patients taking MAO inhibitors within 3 months prior to baseline visit\n* Patients with a known serious adverse reaction to selegiline\n* Patients with a clinically significant psychiatric illness, including a major depression, which compromises their ability to provide consent or participate fully in the study\n* Patients with a Mini Mental State Examination (MMSE) score \\<=24\n* Patients with a diagnosis of melanoma or a history of melanoma, or a suspicious lesion","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary","description":"Parkinson's Disease Patient Diary is a self-administered diary designed to assess motor fluctuations throughout the day. It is divided into 30-minute intervals, and the patient selects one of four options for each interval: asleep; off; on with no dyskinesia or without troublesome dyskinesia; or on with troublesome dyskinesia.\n\nThe Change From Baseline in Mean Total Daily OFF Time is calculated by taking the difference between the average of the total daily OFF time at Weeks 6, 10, 14 and 18, and the Baseline Total Daily OFF Time.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.24","spread":"0.26"},{"groupId":"OG001","value":"-1.59","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Clinical Status Using CGI-I Score During ON Time","description":"Clinical Global Impression - Global Improvement (CGI-I) is a single-item rating scale used to evaluate a patient's condition relative to baseline on a 7-point scale, regardless of whether the improvement is related to the investigational medicinal product (IMP). The scale ranges from 1 (very much improved) to 7 (very much worse).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.35","spread":"0.13"},{"groupId":"OG001","value":"3.05","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in UPDRS-ADL Score During OFF Time","description":"Unified Parkinson's Disease Rating Scale (UPDRS) is a 42-item rating scale designed to assess Parkinson's Disease-related disability and impairment using a patient interview and a physical examination. It has 4 parts and 4 subsection scores. A higher score indicates a worst outcome. I: mentation, behaviour and mood symptoms - 0 to 16; II: activities of daily living (ADL) - 0 to 52; III: motor function - 0 to 108; IV: complications of dopaminergic therapy - 0 to 23. Subsection scores for I to III are used to calculate a total score that ranges from 0 (no disability) to 176 (total dependence).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.42"},{"groupId":"OG001","value":"-0.57","spread":"0.41"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in UPDRS Motor Score During ON Time","description":"UPDRS is a 42-item rating scale designed to assess Parkinson's Disease-related disability and impairment using a patient interview and a physical examination. It has 4 parts and 4 subsection scores. A higher score indicates a worst outcome. I: mentation, behaviour and mood symptoms - 0 to 16; II: ADL - 0 to 52; III: motor function - 0 to 108; IV: complications of dopaminergic therapy - 0 to 23. Subsection scores for I to III are used to calculate a total score that ranges from 0 (no disability) to 176 (total dependence).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.52","spread":"0.72"},{"groupId":"OG001","value":"-2.87","spread":"0.69"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":66},"commonTop":["Dyskinesia","Accidental overdose","Insomnia","Dizziness","Dyspnoea"]}}}